[go: up one dir, main page]

FR07C0031I2 - Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire - Google Patents

Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire

Info

Publication number
FR07C0031I2
FR07C0031I2 FR07C0031C FR07C0031C FR07C0031I2 FR 07C0031 I2 FR07C0031 I2 FR 07C0031I2 FR 07C0031 C FR07C0031 C FR 07C0031C FR 07C0031 C FR07C0031 C FR 07C0031C FR 07C0031 I2 FR07C0031 I2 FR 07C0031I2
Authority
FR
France
Prior art keywords
exendins
agonists
food consumption
reduce food
reduce
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
FR07C0031C
Other languages
English (en)
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
Original Assignee
Amylin Pharmaceuticals LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27488253&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=FR07C0031(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Amylin Pharmaceuticals LLC filed Critical Amylin Pharmaceuticals LLC
Publication of FR07C0031I1 publication Critical patent/FR07C0031I1/fr
Application granted granted Critical
Publication of FR07C0031I2 publication Critical patent/FR07C0031I2/fr
Active legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2207—Gastrins; Cholecystokinins [CCK]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2264—Obesity-gene products, e.g. leptin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/23—Calcitonins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/57563—Vasoactive intestinal peptide [VIP]; Related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Endocrinology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Immunology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
FR07C0031C 1997-01-07 2007-05-16 Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire Active FR07C0031I2 (fr)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US3490597P 1997-01-07 1997-01-07
US5540497P 1997-08-08 1997-08-08
US6602997P 1997-11-14 1997-11-14
US6544297P 1997-11-14 1997-11-14
PCT/US1998/000449 WO1998030231A1 (fr) 1997-01-07 1998-01-07 Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire

Publications (2)

Publication Number Publication Date
FR07C0031I1 FR07C0031I1 (fr) 2007-06-22
FR07C0031I2 true FR07C0031I2 (fr) 2019-06-21

Family

ID=27488253

Family Applications (1)

Application Number Title Priority Date Filing Date
FR07C0031C Active FR07C0031I2 (fr) 1997-01-07 2007-05-16 Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire

Country Status (15)

Country Link
US (10) US6956026B2 (fr)
EP (2) EP1629849B2 (fr)
JP (1) JP4798814B2 (fr)
AT (1) ATE304864T1 (fr)
AU (1) AU739020B2 (fr)
BE (1) BE2007C038I2 (fr)
CA (1) CA2277112C (fr)
DE (2) DE122007000044I2 (fr)
DK (2) DK1629849T4 (fr)
ES (2) ES2247676T3 (fr)
FR (1) FR07C0031I2 (fr)
LU (1) LU91342I2 (fr)
NL (1) NL300281I2 (fr)
PT (1) PT1629849E (fr)
WO (1) WO1998030231A1 (fr)

Families Citing this family (215)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0915910T3 (da) * 1996-06-05 2006-05-22 Roche Diagnostics Gmbh Exendin-analoger, fremgangsmåder til fremstilling deraf samt lægemidlter der indeholder disse
JP2001501593A (ja) * 1996-08-08 2001-02-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 胃腸運動を調節するための方法
EP0941114B1 (fr) * 1996-11-12 2005-02-23 Novo Nordisk A/S Utilisation de peptides glp-1
EP1629849B2 (fr) 1997-01-07 2017-10-04 Amylin Pharmaceuticals, LLC Compositions pharmaceutiques contenant des exendines et leurs agonistes
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
US20040022807A1 (en) * 1998-06-05 2004-02-05 Duft Bradford J Methods for treating obesity
CA2299425A1 (fr) * 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Nouveaux composes agonistes de l'exendine
US7157555B1 (en) 1997-08-08 2007-01-02 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
EP1938831A1 (fr) * 1997-08-08 2008-07-02 Amylin Pharmaceuticals, Inc. Nouveaux composants d'agoniste d'exendine
EP1941900A1 (fr) * 1997-11-14 2008-07-09 Amylin Pharmaceuticals, Inc. Nouveaux composants d'agoniste d'exendine
PT1032587E (pt) * 1997-11-14 2008-04-21 Amylin Pharmaceuticals Inc Novos compostos agonistas de exendina
NZ504258A (en) * 1997-11-14 2002-12-20 Amylin Pharmaceuticals Inc Exendin 3 and 4 agonist compounds for the treatment of diabetes
US7220721B1 (en) 1997-11-14 2007-05-22 Amylin Pharmaceuticals, Inc. Exendin agonist peptides
AU2003200129B2 (en) * 1997-11-14 2006-06-22 Amylin Pharmaceuticals, Llc Novel Exendin Agonist Compounds
AU2006225176B2 (en) * 1997-11-14 2009-01-08 Amylin Pharmaceuticals, Llc Novel exendin agonist compounds
US7223725B1 (en) 1997-11-14 2007-05-29 Amylin Pharmaceuticals, Inc. Exendin agonist compounds
EP1938830A1 (fr) * 1997-11-14 2008-07-02 Amylin Pharmaceuticals, Inc. Nouveaux composants d'agoniste d'exendine
US6998387B1 (en) * 1998-03-19 2006-02-14 Amylin Pharmaceuticals, Inc. Human appetite control by glucagon-like peptide receptor binding compounds
US7259136B2 (en) 1999-04-30 2007-08-21 Amylin Pharmaceuticals, Inc. Compositions and methods for treating peripheral vascular disease
US6429197B1 (en) 1998-10-08 2002-08-06 Bionebraska, Inc. Metabolic intervention with GLP-1 or its biologically active analogues to improve the function of the ischemic and reperfused brain
US6284725B1 (en) * 1998-10-08 2001-09-04 Bionebraska, Inc. Metabolic intervention with GLP-1 to improve the function of ischemic and reperfused tissue
US20030087820A1 (en) * 1999-01-14 2003-05-08 Young Andrew A. Novel exendin agonist formulations and methods of administration thereof
DK1143989T3 (da) * 1999-01-14 2007-04-16 Amylin Pharmaceuticals Inc Exendiner til glucagonundertrykkelse
US7399489B2 (en) 1999-01-14 2008-07-15 Amylin Pharmaceuticals, Inc. Exendin analog formulations
AU777564B2 (en) * 1999-01-14 2004-10-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof
US20050272652A1 (en) 1999-03-29 2005-12-08 Gault Victor A Peptide analogues of GIP for treatment of diabetes, insulin resistance and obesity
WO2000066629A1 (fr) 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Exendines modifiees et agonistes de l'exendine
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US20090175821A1 (en) * 1999-05-17 2009-07-09 Bridon Dominique P Modified therapeutic peptides with extended half-lives in vivo
US6514500B1 (en) * 1999-10-15 2003-02-04 Conjuchem, Inc. Long lasting synthetic glucagon like peptide {GLP-!}
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
US6528486B1 (en) 1999-07-12 2003-03-04 Zealand Pharma A/S Peptide agonists of GLP-1 activity
EP1076066A1 (fr) 1999-07-12 2001-02-14 Zealand Pharmaceuticals A/S Peptides abaissant le taux de glucose sanguin
DK1246638T4 (da) * 2000-01-10 2014-09-22 Amylin Pharmaceuticals Llc Anvendelse af extendiner og agonister deraf til behandlingen af hypertriglyceridæmi
WO2001066135A1 (fr) * 2000-03-08 2001-09-13 Novo Nordisk A/S Reduction des lipides seriques
RU2275207C2 (ru) 2000-12-14 2006-04-27 Амилин Фармасьютикалз, Инк. Способ снижения доступности питательного вещества, способ подавления аппетита
US20090281032A1 (en) * 2001-03-01 2009-11-12 Peter Raymond Flatt Modified CCK peptides
ATE408414T1 (de) * 2001-07-31 2008-10-15 Us Gov Health & Human Serv Glp 1 exendin 4 peptidanaloga und deren verwendungen
GB0121709D0 (en) * 2001-09-07 2001-10-31 Imp College Innovations Ltd Food inhibition agent
NZ532427A (en) * 2001-09-24 2008-07-31 Imp Innovations Ltd Modification of feeding behavior using PYY (peptide YY) and its agonists such as NPY (neuropeptide Y)
WO2003059378A2 (fr) * 2001-12-29 2003-07-24 Novo Nordisk A/S Utilisation combinee d'un compose glp-1 et d'un autre medicament pour traiter la dyslipidemie
WO2003057244A2 (fr) * 2002-01-08 2003-07-17 Amylin Pharmaceuticals, Inc. Utilisation d'agonistes d'amyline en vue de la modulation de triglycerides
US8058233B2 (en) * 2002-01-10 2011-11-15 Oregon Health And Science University Modification of feeding behavior using PYY and GLP-1
CA2472882A1 (fr) * 2002-01-10 2003-07-17 Imperial College Innovations Ltd Utilisation de pyy et de glp-1, ou d'un antagoniste correspondant, pour la modification du comportement alimentaire
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
ES2327328T3 (es) 2002-07-04 2009-10-28 Zealand Pharma A/S Glp-1 y procedimientos para el tratamiento de la diabetes.
RU2376314C2 (ru) 2002-10-02 2009-12-20 Зилэнд Фарма А/С Стабилизированные соединения эксендина-4
AU2003286472A1 (en) * 2002-10-17 2004-05-04 Alkermes Controlled Therapeutics, Inc. Ii Microencapsulation and sustained release of biologically active polypeptides
DK1569680T3 (da) * 2002-10-22 2009-05-18 Waratah Pharmaceuticals Inc Behandling af diabetes
AU2003283216A1 (en) * 2002-12-03 2004-06-23 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones
AU2003256988A1 (en) * 2002-12-11 2004-06-30 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome
US20040209803A1 (en) * 2002-12-19 2004-10-21 Alain Baron Compositions for the treatment and prevention of nephropathy
US7790681B2 (en) * 2002-12-17 2010-09-07 Amylin Pharmaceuticals, Inc. Treatment of cardiac arrhythmias with GLP-1 receptor ligands
US7731947B2 (en) 2003-11-17 2010-06-08 Intarcia Therapeutics, Inc. Composition and dosage form comprising an interferon particle formulation and suspending vehicle
GB0300571D0 (en) * 2003-01-10 2003-02-12 Imp College Innovations Ltd Modification of feeding behaviour
ES2425221T3 (es) * 2003-05-30 2013-10-14 Amylin Pharmaceuticals, Llc Nuevos métodos y composiciones para suministro por vía transmucosa potenciado de péptidos y proteínas
EP1663289A2 (fr) * 2003-08-29 2006-06-07 Amylin Pharmaceuticals, Inc. Procedes pour traiter ou ameliorer des maladies et des troubles associes a la ghreline
KR101135244B1 (ko) 2007-11-29 2012-04-24 한미사이언스 주식회사 인슐린 분비 펩타이드 결합체를 포함하는 비만 관련질환 치료용 조성물
US20060287221A1 (en) 2003-11-13 2006-12-21 Novo Nordisk A/S Soluble pharmaceutical compositions for parenteral administration comprising a GLP-1 peptide and an insulin peptide of short time action for treatment of diabetes and bulimia
US8263084B2 (en) * 2003-11-13 2012-09-11 Hanmi Science Co., Ltd Pharmaceutical composition for treating obesity-related disease comprising insulinotropic peptide conjugate
EP1684793B1 (fr) * 2003-11-13 2011-09-21 Novo Nordisk A/S Composition pharmaceutique comprenant un analogue insulinotrope de glp-1(7-37), de l'insuline-asp(b28), et un surfactant
CN104826116A (zh) 2003-11-20 2015-08-12 诺沃挪第克公司 对于生产和用于注射装置中是最佳的含有丙二醇的肽制剂
WO2005056036A2 (fr) * 2003-12-09 2005-06-23 Novo Nordisk A/S Regulation d'une preference alimentaire au moyen d'agonistes de glp-1
JP2008500281A (ja) 2004-02-11 2008-01-10 アミリン・ファーマシューティカルズ，インコーポレイテッド アミリンファミリーペプチドおよびそれらを作成し使用するための方法
EP2417980A1 (fr) * 2004-02-11 2012-02-15 Amylin Pharmaceuticals Inc. Polypeptides hybrides présentant des propriétés pouvant être choisies
US8076288B2 (en) 2004-02-11 2011-12-13 Amylin Pharmaceuticals, Inc. Hybrid polypeptides having glucose lowering activity
PT1745078E (pt) * 2004-04-23 2009-09-17 Conjuchem Biotechnologies Inc Método para a purificação de conjugados de albumina
US20090069226A1 (en) * 2004-05-28 2009-03-12 Amylin Pharmaceuticals, Inc. Transmucosal delivery of peptides and proteins
US8410047B2 (en) * 2004-06-11 2013-04-02 Novo Nordisk A/S Counteracting drug-induced obesity using GLP-1 agonists
ES2325773T5 (es) 2004-11-01 2014-02-24 Amylin Pharmaceuticals, Llc. Tratamiento de la obesidad y de los trastornos relacionados
AU2005305036B2 (en) * 2004-11-01 2011-03-10 Amylin Pharmaceuticals, Llc Treatment of obesity and related disorders
US8394765B2 (en) * 2004-11-01 2013-03-12 Amylin Pharmaceuticals Llc Methods of treating obesity with two different anti-obesity agents
WO2006074051A2 (fr) * 2004-12-30 2006-07-13 Diakine Therapeutics, Inc. Compositions pharmaceutiques et procedes pour le retablissement de masse et de fonction de cellule $g(b)
US11246913B2 (en) 2005-02-03 2022-02-15 Intarcia Therapeutics, Inc. Suspension formulation comprising an insulinotropic peptide
WO2006083761A2 (fr) 2005-02-03 2006-08-10 Alza Corporation Solutions de solvant/polymere utilisees comme vehicules de suspension
US8263545B2 (en) 2005-02-11 2012-09-11 Amylin Pharmaceuticals, Inc. GIP analog and hybrid polypeptides with selectable properties
WO2006086769A2 (fr) 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Analogues de gip et polypeptides hybrides de gip aux proprietes selectionnables
US7759312B2 (en) * 2005-03-11 2010-07-20 Endo Pharmaceuticals Solutions Inc. Delivery of dry formulations of octreotide
CN101193626A (zh) * 2005-03-11 2008-06-04 益德威士医药股份有限公司 奥曲肽的受控释放制剂
DK1888094T3 (da) * 2005-03-31 2009-11-09 Amylin Pharmaceuticals Inc Amylin og amylinagonister til behandling af psykiatriske sygdomme og forstyrrelser
GB0511986D0 (en) * 2005-06-13 2005-07-20 Imp College Innovations Ltd Novel compounds and their effects on feeding behaviour
EP2330124B1 (fr) * 2005-08-11 2015-02-25 Amylin Pharmaceuticals, LLC Polypeptides hybrides ayant des propriétés sélectionnables
HRP20150186T1 (hr) * 2005-08-19 2015-05-22 Amylin Pharmaceuticals, Llc. Eksendin za lijeäśenje dijabetesa i smanjenje tjelesne težine
WO2007022518A2 (fr) * 2005-08-19 2007-02-22 Amylin Pharmaceuticals, Inc. Nouvelles utilisations de proteines glucoregulatoires
AU2006304836A1 (en) 2005-10-21 2007-04-26 Novartis Ag Combination of a renin-inhibitor and an anti-dyslipidemic agent and/or an antiobesity agent
AU2006312307A1 (en) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Treatment of obesity and related disorders
WO2007055743A2 (fr) * 2005-11-01 2007-05-18 Amylin Pharmaceuticals, Inc. Procédés pour traiter l'obésité et des troubles associés
WO2007053946A1 (fr) * 2005-11-09 2007-05-18 Conjuchem Biotechnologies Inc. Procede de traitement du diabete et/ou de l'obesite en reduisant les effets secondaires nauseeux au moyen d'un peptide insulinotrope conjugue a de l'albumine
CN101316646B (zh) * 2005-11-29 2011-09-21 可隆株式会社 编织物增强的复合空心纤维膜
AU2006329215A1 (en) * 2005-12-22 2007-06-28 Conjuchem Biotechnologies Inc. Process for the production of preformed conjugates of albumin and a therapeutic agent
AU2007267833B2 (en) * 2006-05-26 2012-07-26 Amylin Pharmaceuticals, Llc Composition and methods for treatment of congestive heart failure
MX2008014870A (es) 2006-05-30 2009-02-12 Intarcia Therapeutics Inc Modulador de flujo para sistema de suministro osmotico con canal interno de dos piezas.
ES2371495T3 (es) * 2006-07-24 2012-01-03 Biorexis Pharmaceutical Corporation Proteínas de fusión de exendina.
US20090209469A1 (en) * 2006-08-04 2009-08-20 Dennis Kim Use of Exendins and GLP-1 Receptor Agonists for Altering Lipoprotein Particle Size and Subclass Composition
EP2066337A2 (fr) * 2006-08-04 2009-06-10 Amylin Pharmaceuticals, Inc. Utilisation d'exendines et d'agonistes d'exendines et d'agonistes des récepteurs du glp-1 pour modifier la concentration de fibrinogène
MX2009001114A (es) 2006-08-09 2009-02-10 Intarcia Therapeutics Inc Sistemas de suministro osmotico y ensambles de piston.
NZ574664A (en) * 2006-08-17 2012-06-29 Wellstat Therapeutics Corp Combination treatment for metabolic disorders comprising an incretin mimetic such as exendin or a dppv iv inhibitor
US8497240B2 (en) 2006-08-17 2013-07-30 Amylin Pharmaceuticals, Llc DPP-IV resistant GIP hybrid polypeptides with selectable properties
WO2008023050A1 (fr) * 2006-08-25 2008-02-28 Novo Nordisk A/S Composés d'exendine-4 acylée
KR100872304B1 (ko) * 2006-11-28 2008-12-05 주식회사 코오롱 편물로 보강된 복합 중공사막
TWI428346B (zh) * 2006-12-13 2014-03-01 Imp Innovations Ltd 新穎化合物及其等對進食行為影響
RU2413528C2 (ru) 2007-01-18 2011-03-10 Открытое Акционерное Общество "Валента Фармацевтика" Лекарственный препарат для лечения сахарного диабета на основе экзенатида и даларгина, применение и способ лечения
CN104000779A (zh) 2007-04-23 2014-08-27 精达制药公司 促胰岛素释放肽的混悬制剂及其应用
JP2009019027A (ja) 2007-07-16 2009-01-29 Hanmi Pharmaceutical Co Ltd アミノ末端のアミノ酸が変異したインスリン分泌ペプチド誘導体
BRPI0722276A2 (pt) * 2007-11-14 2014-04-22 Amylin Pharmaceuticals Inc Métodos para tratar obesidade e doenças e distúrbios relacionados à obesidade
EP2231191A2 (fr) * 2007-12-11 2010-09-29 ConjuChem Biotechnologies Inc. Formulation de conjugués de peptides insulinotropes
CA2726861C (fr) 2008-02-13 2014-05-27 Intarcia Therapeutics, Inc. Dispositifs, formulations et methodes d'administration de plusieurs agents benefiques
EP2259791A2 (fr) * 2008-03-05 2010-12-15 Tel HaShomer Medical Research Infrastructure and Services Ltd. Agonistes du récepteur glp-1 et ingrédients pharmaceutiques actifs apparentés pour le traitement du cancer
WO2009143285A2 (fr) 2008-05-21 2009-11-26 Amylin Pharmaceuticals, Inc. Exendines pour diminuer le cholestérol et les triglycérides
JP5622725B2 (ja) * 2008-06-25 2014-11-12 エンド ファーマスーティカルズ ソリューションズ インコーポレイテッド．Ｅｎｄｏ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ Ｓｏｌｕｔｉｏｎｓｉｎｃ． エキセナチド及び他のポリペプチド類の持続的送達
KR20110025974A (ko) * 2008-06-25 2011-03-14 엔도 파마슈티컬즈, 솔루션스 아이엔씨. 이형제를 함유하는 옥트레오티드 이식물
US20110129522A1 (en) * 2008-07-21 2011-06-02 Transpharma Medical Ltd. Transdermal system for extended delivery of incretins and incretn mimetic peptides
BRPI0918904B8 (pt) 2008-09-04 2021-05-25 Amylin Pharmaceuticals Inc formulação pré-misturada fabricada para injeção, seu uso e kit compreendendo a mesma
DE102009038210A1 (de) 2009-08-20 2011-03-03 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
DE102008051834A1 (de) 2008-10-17 2010-04-22 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
HUE068164T2 (hu) 2008-10-17 2024-12-28 Sanofi Aventis Deutschland Egy inzulin és egy GLP-1 agonista kombinációja
DE102008053048A1 (de) 2008-10-24 2010-04-29 Sanofi-Aventis Deutschland Gmbh Kombination von einem Insulin und einem GLP-1-Agonisten
WO2010096394A2 (fr) 2009-02-17 2010-08-26 Redwood Biosciences, Inc. Véhicules de médicaments à base de protéine marqués par aldéhyde et procédés d'utilisation
CN101870728A (zh) 2009-04-23 2010-10-27 派格生物医药(苏州)有限公司 新型Exendin变体及其缀合物
WO2010138671A1 (fr) 2009-05-28 2010-12-02 Amylin Pharmaceuticals, Inc. Composés agonistes du récepteur glp-1 pour amélioration du sommeil
DK2462246T3 (da) 2009-09-28 2017-11-06 Intarcia Therapeutics Inc Hurtig etablering og/eller afslutning af væsentlig steady-state-lægemiddelafgivelse
US20120294855A1 (en) * 2009-11-03 2012-11-22 Eli Lilly & Company Glp-1 receptor agonist compounds for obstructive sleep apnea
SG10201500871TA (en) 2009-11-13 2015-04-29 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine
CA2780460C (fr) 2009-11-13 2018-09-04 Sanofi-Aventis Deutschland Gmbh Composition pharmaceutique comprenant un agoniste de glp-1, une insuline et de la methionine
DE102010011919A1 (de) 2010-03-18 2011-09-22 Sanofi-Aventis Deutschland Gmbh Pharmazeutische Zusammensetzung umfassend einen GLP-1-Agonisten und Methionin
CN102770152B (zh) 2009-11-25 2016-07-06 阿瑞斯根股份有限公司 肽类的粘膜递送
CN102100912B (zh) * 2009-12-16 2015-04-22 上海蓝心医药科技有限公司 一种给药组合物及其制备和使用方法
EP2555791B1 (fr) 2010-04-09 2017-11-01 Sinai Health System Méthodes de traitement de troubles du tractus gastro-intestinal au moyen d'un agoniste glp-1
BR112012027759A2 (pt) 2010-04-27 2017-08-15 Zealand Pharma As Conjugados de peptídeos de agonistas de receptores glp-1 e gastrina e seu uso
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
RS55378B1 (sr) 2010-08-30 2017-03-31 Sanofi Aventis Deutschland Upotreba ave0010 za proizvodnju leka za tretman diabetes mellitus tipa 2
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
EP3028720A1 (fr) 2010-09-28 2016-06-08 Amylin Pharmaceuticals, LLC Polypeptides modifiés à durée d'action accrue
WO2012088157A2 (fr) 2010-12-22 2012-06-28 Amylin Pharmaceuticals, Inc. Agonistes du récepteur de glp-1 pour une transplantation de cellules d'îlot
US9540438B2 (en) 2011-01-14 2017-01-10 Redwood Bioscience, Inc. Aldehyde-tagged immunoglobulin polypeptides and methods of use thereof
US20120208755A1 (en) 2011-02-16 2012-08-16 Intarcia Therapeutics, Inc. Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
EP2714069A4 (fr) 2011-05-25 2015-06-24 Amylin Pharmaceuticals Llc Conjugués de deux hormones longue durée
DK2713722T3 (en) 2011-05-31 2017-07-03 Celgene Int Ii Sarl Newly known GLP-1 receptor stabilizers and modulators
EP2729493B1 (fr) 2011-07-04 2020-06-10 IP2IPO Innovations Limited Nouveaux composés et leurs effets sur le comportement alimentaire
CN104271588B (zh) 2011-07-08 2017-10-10 安米林药品有限责任公司 具有增强的作用持续时间和降低的免疫原性的工程改造的多肽
BR112014004726A2 (pt) 2011-08-29 2017-04-04 Sanofi Aventis Deutschland combinação farmacêutica para uso no controle glicêmico em pacientes de diabetes tipo 2
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US20130096060A1 (en) 2011-10-04 2013-04-18 Jens Stechl Glp-1 agonist for use in the treatment of stenosis or/and obstruction in the pancreatic duct system
EP2763691A1 (fr) 2011-10-04 2014-08-13 Sanofi-Aventis Deutschland GmbH Agoniste du glp-1 pour l'utilisation dans le traitement de la sténose et/ou de l'obstruction dans le tractus biliaire
AU2012331053A1 (en) 2011-11-03 2014-05-29 Zealand Pharma A/S GLP-1 receptor agonist peptide gastrin conjugates
RU2634896C2 (ru) 2011-12-12 2017-11-08 Селджин Интернэшнл Ii Сарл Новые модуляторы рецептора glp-1
AR091422A1 (es) 2012-06-14 2015-02-04 Sanofi Sa Analogos peptidicos de la exendina 4
BR112015001451B1 (pt) 2012-07-23 2022-03-29 Zealand Pharma A/S Composto, construção de ácido nucleico, vetor de expressão, célula hospedeira, composição farmacêutica, utilização de um composto ou de seu sal ou solvato farmaceuticamente aceitável
TWI608013B (zh) 2012-09-17 2017-12-11 西蘭製藥公司 升糖素類似物
UA116217C2 (uk) 2012-10-09 2018-02-26 Санофі Пептидна сполука як подвійний агоніст рецепторів glp1-1 та глюкагону
PT2934568T (pt) 2012-12-21 2018-01-04 Sanofi Sa Agonistas duplos de glp1/gip ou trigonais de glp1/gip/glucagina
KR101581497B1 (ko) 2013-01-24 2015-12-30 강원대학교산학협력단 인삼열매 추출물을 포함하는 파킨슨병과 알츠하이머병의 예방 또는 치료용 조성물
TWI641381B (zh) 2013-02-04 2018-11-21 法商賽諾菲公司 胰島素類似物及／或胰島素衍生物之穩定化醫藥調配物
DK2968471T3 (en) 2013-03-01 2017-10-23 Fundació Hospital Univ Vall D' Hebron - Inst De Recerca Peptides for use in the topical treatment of retinal neurodegenerative diseases, especially in early stages of diabetic retinopathy and other retinal diseases in which neurodegeneration plays an essential role
EP4424697A3 (fr) 2013-06-05 2024-12-25 Bausch Health Ireland Limited Agonistes ultra-purs de guanylate cyclase c, leur procédé de fabrication et d'utilisation
KR102271179B1 (ko) 2013-06-11 2021-07-01 셀진 인터내셔널 Ii 에스에이알엘 신규의 glp-1 수용체 조절제
US9988429B2 (en) 2013-10-17 2018-06-05 Zealand Pharma A/S Glucagon analogues
MX368436B (es) 2013-10-17 2019-10-03 Zealand Pharma As Analogos de glucagon acilados.
CA2928526A1 (fr) 2013-11-01 2015-05-07 Spherium Biomed S.L. Corps d'inclusion pour administration transdermique d'agents therapeutiques et cosmetiques
CA2929459C (fr) 2013-11-06 2022-05-03 Zealand Pharma A/S Composes agonistes doubles de gip et glp-1 et procedes associes
KR102310392B1 (ko) 2013-11-06 2021-10-13 질랜드 파마 에이/에스 글루카곤-ｇｌｐ-1-ｇｉｐ 삼원 효능제 화합물
TW201609799A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／ｇｉｐ受體促效劑
TW201609795A (zh) 2013-12-13 2016-03-16 賽諾菲公司 作為雙重ｇｌｐ－１／ｇｉｐ受體促效劑的艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609796A (zh) 2013-12-13 2016-03-16 賽諾菲公司 非醯化之艾塞那肽－４（ｅｘｅｎｄｉｎ－４）胜肽類似物
TW201609797A (zh) 2013-12-13 2016-03-16 賽諾菲公司 雙重ｇｌｐ－１／升糖素受體促效劑
SG11201604706TA (en) 2014-01-09 2016-07-28 Sanofi Sa Stabilized pharmaceutical formulations of insulin aspart
WO2015104311A1 (fr) 2014-01-09 2015-07-16 Sanofi Formulations pharmaceutiques stabilisées sans glycérol d'analogues de l'insuline et/ou de dérivés de l'insuline
EP3091995B1 (fr) 2014-01-09 2024-03-20 Sanofi Formulations pharmaceutiques stabilisées d'insuline aspart
TW201625669A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自艾塞那肽－４（Ｅｘｅｎｄｉｎ－４）之肽類雙重ＧＬＰ－１／升糖素受體促效劑
TW201625670A (zh) 2014-04-07 2016-07-16 賽諾菲公司 衍生自ｅｘｅｎｄｉｎ－４之雙重ｇｌｐ－１／升糖素受體促效劑
TW201625668A (zh) 2014-04-07 2016-07-16 賽諾菲公司 作為胜肽性雙重ｇｌｐ－１／昇糖素受體激動劑之艾塞那肽－４衍生物
US9932381B2 (en) 2014-06-18 2018-04-03 Sanofi Exendin-4 derivatives as selective glucagon receptor agonists
AU2015292356B2 (en) 2014-07-25 2020-02-06 Receptos Llc Novel GLP-1 receptor modulators
RU2573933C1 (ru) 2014-08-21 2016-01-27 Дафот Энтерпрайсис Лимитед Пептид для лечения сахарного диабета 2-го типа и его осложнений
BR112017003745A2 (pt) 2014-08-29 2017-12-05 Tes Pharma S R L inibidores de semialdeído descarboxilase de ácido alfa-amino-beta-carboximucônico
US9889085B1 (en) 2014-09-30 2018-02-13 Intarcia Therapeutics, Inc. Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
ES2883345T3 (es) 2014-10-29 2021-12-07 Zealand Pharma As Compuestos agonistas del GIP y métodos
CA2969944A1 (fr) 2014-12-10 2016-06-16 Celgene International Ii Sarl Nouveaux modulateurs du recepteur du glp-1
TWI758239B (zh) 2014-12-12 2022-03-21 德商賽諾菲阿凡提斯德意志有限公司 甘精胰島素/利司那肽固定比率配製劑
CA2979033A1 (fr) 2015-03-09 2016-09-15 Intekrin Therapeutics, Inc. Methodes de traitement de la steatose hepatique non alcoolique et/ou de la lipodystrophie
TWI748945B (zh) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患治療
TW201705975A (zh) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 第２型糖尿病病患之治療
PL3283507T3 (pl) 2015-04-16 2020-05-18 Zealand Pharma A/S Acylowany analog glukagonu
LT3297653T (lt) 2015-05-22 2022-01-10 The Board Of Trustees Of The Leland Stanford Junior University Postbariatrinės hipoglikemijos gydymas glp-1 antagonistais
US10925639B2 (en) 2015-06-03 2021-02-23 Intarcia Therapeutics, Inc. Implant placement and removal systems
AR105319A1 (es) 2015-06-05 2017-09-27 Sanofi Sa Profármacos que comprenden un conjugado agonista dual de glp-1 / glucagón conector ácido hialurónico
TW201706291A (zh) 2015-07-10 2017-02-16 賽諾菲公司 作為選擇性肽雙重ｇｌｐ－１／升糖素受體促效劑之新毒蜥外泌肽（ｅｘｅｎｄｉｎ－４）衍生物
US10677956B2 (en) * 2015-10-01 2020-06-09 Schlumberger Technology Corporation Active damping for NMR logging tools
MX391259B (es) 2015-10-14 2025-03-21 X Therma Inc Composiciones y métodos para reducir la formación de cristales de hielo.
US10294303B2 (en) 2015-12-23 2019-05-21 Amgen Inc. Method of treating or ameliorating metabolic disorders using binding proteins for gastric inhibitory peptide receptor (GIPR) in combination with GLP-1 agonists
WO2017152014A1 (fr) 2016-03-04 2017-09-08 Eiger Biopharmaceuticals, Inc. Traitement de l'hypoglycémie hyperinsulinémique avec des dérivés de l'exendine-4
US11207415B2 (en) 2016-04-15 2021-12-28 Syracuse University Peptide drug improvement using vitamin B12 and haptocorrin binding substrate conjugates
JP2019515677A (ja) 2016-04-26 2019-06-13 アール．ピー．シェーラー テクノロジーズ エルエルシー 抗体複合体ならびにそれを作製および使用する方法
MA53353A (fr) 2016-05-16 2021-06-09 Intarcia Therapeutics Inc Polypeptides sélectifs pour le récepteur du glucagon et méthodes pour leur utilisation
USD840030S1 (en) 2016-06-02 2019-02-05 Intarcia Therapeutics, Inc. Implant placement guide
USD860451S1 (en) 2016-06-02 2019-09-17 Intarcia Therapeutics, Inc. Implant removal tool
US20190224122A1 (en) 2016-09-23 2019-07-25 Delpor, Inc. Stable compositions for incretin mimetic compounds
TWI767945B (zh) 2016-10-14 2022-06-21 義大利商Ｔｅｓ製藥（股份）責任有限公司 α-胺基-β-羧基己二烯二酸半醛去羧酶之抑制劑
DK3541366T3 (da) 2016-11-21 2025-03-03 Amylyx Pharmaceuticals Inc Bufferformuleringer af exendin (9-39)
WO2018104263A1 (fr) 2016-12-06 2018-06-14 INSERM (Institut National de la Santé et de la Recherche Médicale) Procédés d'amélioration de l'activité de médicaments à base d'incrétine chez des sujets en ayant besoin
CA3043151A1 (fr) 2016-12-09 2018-06-14 Zealand Pharma A/S Agonistes doubles de glp-1/glp-2 acyles
KR20190104039A (ko) 2017-01-03 2019-09-05 인타르시아 세라퓨틱스 인코포레이티드 Glp-1 수용체 효능제의 연속적인 투여 및 약물의 동시-투여를 포함하는 방법
JOP20190177A1 (ar) 2017-01-17 2019-07-16 Amgen Inc طريقة لعلاج أو تحسين اضطرابات أيضية باستخدام مساعدات مستقبل glp-1 مقترنة بمناهضات لمستقبل ببتيد مثبط معوي (gipr)
CN110996951A (zh) 2017-04-03 2020-04-10 科赫罗斯生物科学股份有限公司 治疗进行性核上性麻痹的PPARγ激动剂
BR112019024410A2 (pt) 2017-06-20 2020-07-14 Amgen Inc. método de tratamento ou melhoria de disfunções metabólicas usando proteínas de ligação para receptor do peptídeo inibidor gástrico (gipr) em combinação com agonistas de glp 1
MX2019015544A (es) 2017-06-21 2020-07-28 Amgen Inc Metodo para tratar o mejorar trastornos metabolicos con proteinas de fusion de agonistas del receptor de glp-1/proteinas de union antagonistas para el receptor peptidico inhibidor gastrico (gipr).
EP3474820B1 (fr) 2017-08-24 2024-02-07 Novo Nordisk A/S Compositions glp-1 et ses utilisations
DK3774838T3 (da) 2018-04-10 2022-10-31 Sanofi Aventis Deutschland Lixisenatidsyntese med capping
WO2019197466A1 (fr) 2018-04-10 2019-10-17 Sanofi-Aventis Deutschland Gmbh Procédé de clivage de peptides liés à une phase solide à partir de la phase solide
CN113302189B (zh) 2018-11-20 2025-09-05 Tes制药有限责任公司 α-氨基-β-羧基己二烯二酸半醛去羧酶的抑制剂
WO2020185533A1 (fr) 2019-03-08 2020-09-17 Amgen Inc. Polythérapie par facteur de différenciation de croissance 15
PE20230819A1 (es) 2020-02-18 2023-05-19 Novo Nordisk As Composiciones y usos de glp-1
WO2024123812A1 (fr) 2022-12-05 2024-06-13 Shattuck Labs, Inc. Protéines de fusion pour le traitement de maladies cardiométaboliques

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5120712A (en) 1986-05-05 1992-06-09 The General Hospital Corporation Insulinotropic hormone
US5118666A (en) 1986-05-05 1992-06-02 The General Hospital Corporation Insulinotropic hormone
US5175145A (en) * 1988-08-26 1992-12-29 Amylin Pharmaceuticals, Inc. Treatment of diabetes mellitus with amylin agonists
JPH04504246A (ja) 1989-03-20 1992-07-30 ザ・ジェネラル・ホスピタル・コーポレーション インシュリン刺激ホルモン
WO1991011457A1 (fr) 1990-01-24 1991-08-08 Buckley Douglas I Analogues de glp-1 utiles dans le traitement du diabete
US5545618A (en) 1990-01-24 1996-08-13 Buckley; Douglas I. GLP-1 analogs useful for diabetes treatment
US5187154A (en) * 1990-12-13 1993-02-16 Board Of Regents, The University Of Texas System Diagnosis and treatment of humans with diabetes or at risk to develop diabetes
US5264372A (en) * 1991-03-15 1993-11-23 Amylin Pharmaceuticals, Inc. Receptor-based screening methods for amylin agonists and antagonists
HU222249B1 (hu) * 1991-03-08 2003-05-28 Amylin Pharmaceuticals Inc. Eljárás amilin agonista peptidszármazékok és ezeket tartalmazó gyógyszerkészítmények előállítására
DK36392D0 (da) 1992-03-19 1992-03-19 Novo Nordisk As Anvendelse af kemisk forbindelse
JP2575298B2 (ja) 1992-06-15 1997-01-22 フアイザー・インコーポレイテツド グルカゴン様ペプチド及びインシュリノトロピン誘導体
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
US5424289A (en) * 1993-07-30 1995-06-13 Alza Corporation Solid formulations of therapeutic proteins for gastrointestinal delivery
DE69426304T2 (de) 1993-09-07 2001-03-15 Amylin Pharmaceuticals, Inc. Methoden zur regulation der den magen und darm betreffenden motilitaet
CA2171281C (fr) 1993-09-09 1998-12-29 Romeo Rang Compositions immunomodulatrices provenant de la bile
US5705483A (en) 1993-12-09 1998-01-06 Eli Lilly And Company Glucagon-like insulinotropic peptides, compositions and methods
EP0788371A1 (fr) * 1994-08-26 1997-08-13 LEE, Nancy M. Procede analgesique utilisant des analogues de dynorphine tronques au niveau de la terminaison n
US5574008A (en) 1994-08-30 1996-11-12 Eli Lilly And Company Biologically active fragments of glucagon-like insulinotropic peptide
US5641425A (en) * 1994-09-08 1997-06-24 Multiform Desiccants, Inc. Oxygen absorbing composition
US5512549A (en) 1994-10-18 1996-04-30 Eli Lilly And Company Glucagon-like insulinotropic peptide analogs, compositions, and methods of use
US5739106A (en) * 1995-06-07 1998-04-14 Rink; Timothy J. Appetite regulating compositions
IL122718A0 (en) * 1995-06-30 1998-08-16 Lilly Co Eli Methods for treating diabetes
SE9600608L (sv) 1996-02-19 1997-02-17 Kavlugnt Ab Kopplingsanordning för sammankoppling av ett arbetsredskap till en arbetsmaskin; både mekanisk hopkoppling och snabbkoppling av hydraullikkopplingarna
DK0915910T3 (da) * 1996-06-05 2006-05-22 Roche Diagnostics Gmbh Exendin-analoger, fremgangsmåder til fremstilling deraf samt lægemidlter der indeholder disse
US5686511A (en) 1996-06-28 1997-11-11 The Valspar Corporation Esterifying epoxy resin with carboxyl polymer and quenching
WO1998005331A2 (fr) 1996-08-02 1998-02-12 Ligand Pharmaceuticals Incorporated Prevention ou traitement de diabetes non insulinodependants ou de maladies cardiovasculaires avec des modulateurs ppar
JP2001501593A (ja) * 1996-08-08 2001-02-06 アミリン・ファーマシューティカルズ，インコーポレイテッド 胃腸運動を調節するための方法
UA65549C2 (uk) 1996-11-05 2004-04-15 Елі Ліллі Енд Компані Спосіб регулювання ожиріння шляхом периферійного введення аналогів та похідних glp-1 (варіанти) та фармацевтична композиція
US5677279A (en) * 1996-12-16 1997-10-14 Amylin Pharmaceuticals, Inc. Methods and compositions for treating pain with amylin or agonists thereof
EP1629849B2 (fr) * 1997-01-07 2017-10-04 Amylin Pharmaceuticals, LLC Compositions pharmaceutiques contenant des exendines et leurs agonistes
US5830904A (en) * 1997-02-05 1998-11-03 University Of Kentucky Research Foundation Lobeline compounds as a treatment for psychostimulant abuse and withdrawal, and for eating disorders
US5846937A (en) 1997-03-03 1998-12-08 1149336 Ontario Inc. Method of using exendin and GLP-1 to affect the central nervous system
US7910548B2 (en) * 1997-06-06 2011-03-22 Amylin Pharmaceuticals, Inc. Methods for treating obesity
CA2299425A1 (fr) 1997-08-08 1999-02-18 Amylin Pharmaceuticals, Inc. Nouveaux composes agonistes de l'exendine
PL343851A1 (en) 1997-12-12 2001-09-10 Warner Lambert Co Antihyperlipidemic statin-lp(a) inhibitor combinations
US6187777B1 (en) * 1998-02-06 2001-02-13 Amgen Inc. Compounds and methods which modulate feeding behavior and related diseases
SE9801992D0 (sv) 1998-06-04 1998-06-04 Astra Ab New 3-aryl-2-hydroxypropionic acid derivative I
US6783942B2 (en) * 1998-10-08 2004-08-31 Uab Research Foundation Isolated polynucleotide associated with type II diabetes mellitus and methods of use thereof
US6326396B1 (en) * 1998-11-20 2001-12-04 Alteon, Inc. Glucose and lipid lowering compounds
AU777564B2 (en) * 1999-01-14 2004-10-21 Amylin Pharmaceuticals, Inc. Novel exendin agonist formulations and methods of administration thereof
US6153432A (en) * 1999-01-29 2000-11-28 Zen-Bio, Inc Methods for the differentiation of human preadipocytes into adipocytes
WO2000066629A1 (fr) 1999-04-30 2000-11-09 Amylin Pharmaceuticals, Inc. Exendines modifiees et agonistes de l'exendine
US6924264B1 (en) * 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6506724B1 (en) * 1999-06-01 2003-01-14 Amylin Pharmaceuticals, Inc. Use of exendins and agonists thereof for the treatment of gestational diabetes mellitus
DK1246638T4 (da) * 2000-01-10 2014-09-22 Amylin Pharmaceuticals Llc Anvendelse af extendiner og agonister deraf til behandlingen af hypertriglyceridæmi
US6608038B2 (en) * 2000-03-15 2003-08-19 Novartis Ag Methods and compositions for treatment of diabetes and related conditions via gene therapy
US7232798B2 (en) * 2001-11-13 2007-06-19 Tran Loi H Neuroprotection and neuroegenisis by administering cyclic prolyl glycine
US7105489B2 (en) * 2002-01-22 2006-09-12 Amylin Pharmaceuticals, Inc. Methods and compositions for treating polycystic ovary syndrome

Also Published As

Publication number Publication date
WO1998030231A1 (fr) 1998-07-16
NL300281I1 (nl) 2007-09-03
DE122007000044I1 (de) 2011-02-10
US20050043238A1 (en) 2005-02-24
DK1629849T4 (en) 2017-12-04
DK1629849T3 (da) 2013-08-12
EP0996459B1 (fr) 2005-09-21
LU91342I9 (fr) 2018-12-31
ATE304864T1 (de) 2005-10-15
EP1629849A3 (fr) 2006-04-26
DK0996459T3 (da) 2006-01-16
CA2277112A1 (fr) 1998-07-16
US7741269B2 (en) 2010-06-22
US7419952B2 (en) 2008-09-02
BE2007C038I2 (en) 2018-01-12
US20020137666A1 (en) 2002-09-26
US7297761B2 (en) 2007-11-20
DE69831673D1 (de) 2005-10-27
US7115569B2 (en) 2006-10-03
US7138375B2 (en) 2006-11-21
ES2425559T3 (es) 2013-10-16
DE122007000044I2 (de) 2011-05-05
US20090176704A1 (en) 2009-07-09
US20030087821A1 (en) 2003-05-08
DE69831673C5 (de) 2015-01-22
LU91342I2 (fr) 2007-12-06
AU6239498A (en) 1998-08-03
AU739020B2 (en) 2001-10-04
PT1629849E (pt) 2013-07-09
EP0996459A4 (fr) 2002-04-10
EP1629849A2 (fr) 2006-03-01
JP4798814B2 (ja) 2011-10-19
HK1025252A1 (en) 2000-11-10
US7700549B2 (en) 2010-04-20
US20050215469A1 (en) 2005-09-29
US8288338B2 (en) 2012-10-16
US20050059601A1 (en) 2005-03-17
JP2002508742A (ja) 2002-03-19
EP1629849B1 (fr) 2013-05-22
US20110034377A1 (en) 2011-02-10
FR07C0031I1 (fr) 2007-06-22
DE69831673T2 (de) 2006-06-22
US6956026B2 (en) 2005-10-18
EP0996459A1 (fr) 2000-05-03
NL300281I2 (nl) 2018-01-23
EP1629849B2 (fr) 2017-10-04
CA2277112C (fr) 2008-08-26
US20130023470A1 (en) 2013-01-24
US20060148713A1 (en) 2006-07-06
US6989366B2 (en) 2006-01-24
US20050101537A1 (en) 2005-05-12
ES2425559T5 (es) 2018-02-02
ES2247676T3 (es) 2006-03-01

Similar Documents

Publication Publication Date Title
FR07C0031I2 (fr) Utilisation d'exendines et de leurs agonistes pour reduire la consommation alimentaire
PT1270565E (pt) Furano-2-sulfonamida 4-substituida e sua utilizacao na preparacao de derivados de sulfonilureia
EP0793501A4 (fr) Activation in vivo de lymphocytes t cytotoxiques specifiques de tumeurs
FR2770776B1 (fr) Utilisations du d-xylose et de ses esters pour ameliorer la fonctionnalite des cellules de l'epiderme
DE69733198D1 (de) Überlaufnachweis von roten blutzellen
EP1018987A4 (fr) Neocartilage et ses methodes d'utilisation
IL118247A0 (en) Use of R-enantiomer of N-propargyl-1-aminoindan and its salts
FR2765801B1 (fr) Utilisation de monoesters d'arbutine comme agent depigmentant
FI964078A7 (fi) Ultraäänen käyttö paperinvalmistuksen yhteydessä
FR2827170B1 (fr) Utilisation de peptides pour augmenter l'adhesion cellulaire
ID23447A (id) Pengolahan untuk membuat derifat-derifat pirazol
ZA985274B (en) Improvements in or relating to the cleansing of surfaces
NO20012011D0 (no) Fremstilling og anvendelse av stivnede oljer
PT1025100E (pt) Derivados de tetra-hidropiridopirimidona substituidos na posicao 3 sua preparacao e sua utilizacao
DE69623593D1 (de) Feststoffe enthaltend valproinsäure und natriumvalproat
FR2715802B1 (fr) Utilisation d'enzymes dans l'alimentation des animaux pour réduire les rejets azotés.
DE69316417D1 (de) Reduzierung des Stromverbrauches in Mikroprozessoren
FR2765482B1 (fr) Utilisation de l'acide y-linolenique pour prevenir le stress oxydatif
ID24940A (id) Pemakaian ketolida-ketolida untuk pencegahan komplikasi trombotik arteri mengenai aterosklerosis
ID29352A (id) Penggunaan turunan tiazolidindion untuk mencegah kontraksi uterin dalam persalinan prematur atau laktasi
EP0711156A4 (fr) Utilisation de l'acide n-methyle-aspartique pour renforcer la croissance et modifier la composition corporelle
FR2777291B1 (fr) Nouvelle metalloprotease membranaire nep ii et son utilisation pour le criblage d'inhibiteurs utiles en therapie
FR2794967B1 (fr) Ogive dilatatrice introduite entre des surfaces osseuses articulaires concaves pour en restaurer l'ecartement et la position angulaire
EE04456B1 (et) Laeva tsentraalne läbiveokanal ja selle kasutamine
GB9726965D0 (en) Transfer of basic knowledge to agents